the carbohydrate shell, blood samples were co-treated with the iron chelator, desferrioxamine. Results: Iron sucrose caused significant PMN apoptosis and dose-dependent suppression of phagocytic function against both Gram-positive and Gram-negative bacteria. These abnormalities were prevented by desferrioxamine which precluded contribution of the carbohydrate shell to the PMN dysfunction. Conclusions: At pharmacologically-relevant concentrations, iron sucrose promotes apoptosis and inhibits phagocytic activities of PMNs. The deleterious effect of iron sucrose is mediated by its elemental iron core, not its carbohydrate shell, and as such may be shared by other IV iron preparations.
dendritic cells [7] , diminished numbers and reduced antibody-producing capacity of B lymphocyte [4, [8] [9] [10] , increased T-cell turnover and apoptosis culminating in depletion of naive and central memory CD4+ and CD8+ T lymphocytes [11, 12] , impaired cell-mediated immunity [4, 13] and reduced granulocyte and monocyte/macrophage phagocytic function [4, 14, 15] . Iron overload has been shown to be associated with an increased incidence of bacterial infections in patients with and without ESRD [8, 16, 17] , and polymorphonuclear leukocyte (PMN) phagocytic functions appear to be depressed in patients with iron overload [18] [19] [20] [21] [22] . With recent implementation of bundling reimbursement policy, the use of intravenous (IV) iron preparations in ESRD patients has dramatically increased [23] . This approach has been adopted by dialysis facilities in an attempt to reduce the cost of anemia treatment by limiting the use of erythropoiesis-stimulating agents (ESA). In many instances, IV iron preparations are administered on a routine basis with insufficient attention to the total body iron stores. In fact, excessive use of IV iron compounds has led to an epidemic of iron overload in the dialysis population [24, 25] . In an elegant study, Deicher et al. [18] evaluated phagocytosis and killing of Escherichia coli before, during, 1 h, and 2 days after IV administration of 300 mg iron sucrose in a group of 10 ESRD patients maintained on peritoneal dialysis. The results were compared to those obtained in 10 placebotreated patients. They found a significant reduction in the absolute count and percentage of E. coli killed by PMNs of the iron sucrose-treated peritoneal dialysis patients over time as compared to values found in the placebotreated patients. These observations provided compelling evidence for the inhibitory action of iron sucrose on neutrophilic granulocytes in this population.
IV iron preparations consist of a core of elemental iron covered by a carbohydrate envelope. In addition to the elemental iron contained in the core of the parenteral iron products, their carbohydrate shell may potentially affect PMNs and monocytes. For instance, it is conceivable that the carbohydrate shell of these products may be detected by the pattern recognition receptors such as toll-like receptor (TLR)2 and TLR4 expressed on the PMN and monocyte plasma membrane. If true, binding of the complex carbohydrate shell of IV iron products to these receptors can result in activation of PMNs and monocytes and thereby limit or preclude their participation in the phagocytosis and killing of the invading bacteria in vivo or in the in vitro laboratory setting. The present study was designed to examine the effect of one of the commonly used IV iron preparations, iron sucrose, on the phagocytic capacity of PMNs from a group of normal individuals against Gram-positive (Staphylococcus aureus) and Gramnegative (E. coli) bacteria. To this end, iron sucrose was added to heparinized blood samples from each subject at pharmacologically relevant concentrations and incubated for 4 and 24 h at 37 ° C to simulate in vivo condition. Blood samples mixed with an equal volume of saline solution served as controls. To isolate the possible effect of the complex carbohydrate shell from that of the elemental iron core of the drug, blood samples were simultaneously treated with iron sucrose and the iron chelator, desferrioxamine. In addition to IV iron preparations and iron overload, dialysis procedure, uremic toxins, dialyzer bioincompatibility, underlying illnesses, and the prevailing systemic inflammation can contribute to the PMN dysfunction [26] . We elected to use blood samples from normal individuals to isolate the effect of iron sucrose per se from those of uremic toxins, dialysis-related factors and systemic inflammation. The study showed that iron sucrose causes a significant dose-dependent suppression of phagocytic activities of PMNs against both Gram-positive and Gram-negative bacteria. Iron sucrose-induced suppression of PMN phagocytic activity was prevented by cotreatment with iron chelator, desferrioxamine, thus precluding the contribution of the carbohydrate shell of iron sucrose to the PMN dysfunction. In addition, we compared the extent of apoptosis in blood samples incubated with or without iron sucrose. Iron sucrose significantly increased PMN apoptosis in a dose-dependent manner.
Materials and Methods

Blood Collection and Study Participants
Ten healthy individuals, 3 women and 7 men, aged 21-43 years participated in this study. The study protocol was approved by the Institutional Review Board of the University of California Irvine (HS# 2007-5572) and completed with the assistance of the University of California, Irvine General Clinical Research Center. Written informed consent was obtained from all subjects. Blood samples were obtained by venipuncture and gently placed into the heparinized tubes and processed as described below. Each blood sample was divided into multiple aliquots to which iron sucrose (American Regent, Inc., Shirley, N.Y., USA) was added to reach the final concentrations of 20, 100 and 200 mg/l. The rationale for the choice of these concentrations was based on the anticipated plasma levels following administration of the approved doses of IV iron products considering the blood volume of about 5 liters of which 60-70% is plasma where the drug is distributed. Given the large size of the iron complex, the distribution of the product is largely limited to plasma. Aliquots mixed with the vehicle served as controls. The samples were then incubated for 4 and 24 h at 37 ° C in a humidified incubator prior to flow cytometric analysis.
Assessment of Phagocytosis by Flow Cytomery
The detection of phagocytosis in PMNs was carried out with pHrodo TM E. coli and pHrodo TM S. aureus BioParticles Phagocytosis Kits (Invitrogen, Calsbad, Calif., USA). The pHrodo TM dye becomes fluorescent upon acidification in endocytic compartments, which directly relates to phagocytosis of the labeled particles. pHrodo-labeled E. coli and S. aureus BioParticles (20 l) were incubated with aliquots of whole peripheral blood that was pretreated with different concentrations of iron. After a 15-min incubation at 37 ° C, erythrocytes were lysed, washed with PBS and the samples were analyzed by flow cytometry (FACSCalibur, BD Biosciences). Forward and side scatter was used to gate the PMN and phagocytic uptake was determined by measuring fluorescence signal emitted by endocytosed bacteria. Results are expressed as % phagocytosis of the control group. CellQuest software was used for analysis (Becton-Dickinson, San Jose, Calif., USA).
Detection of TLR2 or TLR4 Expression by Flow Cytomery
After the incubation for 24 h at 37 ° C with iron, TLRs were stained using the following antibodies: Alexa Fluor 488-conjugated anti-human TLR2 (eBioscience, San Diego, Calif., USA) and Alexa Fluor 488-conjugated anti-human TLR4 (eBioscience). Mouse IgG2a K Isotype Control Alexa Fluor 488 (eBioscience) was used as a negative control. The samples were incubated with each antibody in the dark room at 4 ° C for 20 min, and were washed twice with PBS before FACS analysis.
Viability Assessment by Flow Cytomery
Apoptosis was measured using Annexin V-FITC Apoptosis Detection Kit (BioVision). After incubation for 24 h at 37 ° C, the red blood cell contents of the test samples were lysed by ACK lysing, washed, resuspend in annexin binding buffer and stained with FITC-labeled Annexin V and propidium iodide (PI), 50,000 cells from each sample were assessed by flow cytometry (FACSCalibur, Becton-Dickinson). CellQuest software was used for analysis (Becton-Dickinson).
Statistical Analysis
Student's t test and one-way analysis of variance (ANOVA) were used in statistical analysis of the data using Excel for Windows software (Microsoft, Redmond, Wash., USA). p values ^ 0.05 were considered significant. Data are expressed as mean 8 SD.
Results
Effects of Iron on Phagocytic Function of PMNs
Incubation with iron sucrose for 4 h caused a significant concentration-dependent suppression of phagocytic activity of PMNs against S. aureus (data are depicted in fig. 1 a) . Likewise, 4-hour incubation with iron sucrose caused a significant concentration-dependent inhibition of PMN phagocytic activity against E. coli (data are shown in fig. 1 b) . Similarly, incubation with iron sucrose for 24 h resulted in significant reduction of phagocytic function of PMNs against negative bacteria (data are shown in fig. 1 c) .
To exclude the possible effect of the complex carbohydrate shell from that of the elemental iron core of the drug, blood samples were simultaneously treated with iron sucrose and the iron chelator, desferrioxamine (50 mol/l). The iron sucrose-induced suppression of PMN phagocytotic activity was completely prevented by desferrioxamine ( fig. 2 ) . These findings provide irrefutable evidence for the role of iron core and preclude the contribution of the carbohydrate shell of iron sucrose to the observed PMN dysfunction.
Effects of Iron on TLR2 and TLR4 Expression in PMNs
TLRs play an essential role in the detection of invading pathogens. TLR2 and TLR4 are expressed on PMNs and serve a critical role in host defenses against Gram-positive and Gram-negative bacteria, respectively. TLR2 recognizes the peptidoglycans on Gram-positive organism, whereas TLR4 recognizes the conserved lipopolysaccharide pattern of Gram-negative bacteria. Exposure to these ligands results in upregulation and activation of these receptors which, in turn, lead to leukocyte activation, cytokine production, and phagocytosis of the given bacteria. We, therefore, asked if the observed suppression of PMN phagocytic function by iron sucrose is associated with and, in part, mediated by changes in TLR2 and TLR4 expressions. The study revealed no significant effect on either TLR2 or TLR4 expression on PMN in response to iron sucrose at either 4 or 24 h (mean fluorescence intensity: control, 20, 100 mg/l = TLR2; 61.1 8 3.1, 58.3 8 2.4, 62.8 8 2.8, TLR4; 22.5 8 2.5, 23.7 8 3.1, 25.2 8 2.9, respectively, p = NS; fig. 3 ).
Effects of Iron Sucrose on PMN Viability and Apoptosis
Annexin V and PI staining was used to investigate the PMN viability in blood samples incubated with or without iron sucrose for 4 or 24 h. There was no significant difference in Annexin V and PI staining at 4 h. However, iron sucrose resulted in a significantly concentration-dependent increase in the apoptotic PMNs (Annexin V (positive) PI (negative)) ( fig. 4 ) . The presence of significant impairment of phagocytic activity of PMNs despite preservation of their viability within the 4-hour exposure to iron sucrose suggests that the inhibitory effect of this compound is independent of its cytocidal action which requires longer exposure. 
Discussion
The present study showed that pharmacologically relevant concentrations of iron sucrose significantly suppressed the phagocytic function of PMNs from healthy donors in a dose-dependent manner against both Grampositive (S. aureus) and Gram-negative bacteria (E. coli) . The molecules expressed on the wall of Gram-positive bacterial (peptidoglycans) and Gram-negative bacteria (lipopolysaccharides) are recognized by pattern recognition receptors, TLR2 and TLR4, respectively. These receptors are expressed on PMNs, monocytes, and macrophages. Exposure to these ligands results in upregulation and activation of these receptors which, in turn, lead to leukocyte activation, cytokine production, and phagocytosis of the given bacteria. To explore the possibility that iron sucrose-induced suppression of phagocytic activity of PMNs against Gram-positive and Gram-negative bacteria is mediated by modulation of TLR2 or TLR4 expression, we examined the expression of these receptors on PMNs in blood samples incubated with iron sucrose. The experiments revealed no significant change in either TLR2 or TLR4 expression in PMNs with this iron preparation.
To dissect the contribution of iron core from the carbohydrate shell of iron sucrose to the observed suppression of PMNs' phagocytic activity, we examined the effect of co-incubation of blood samples with iron sucrose and iron chelator, desferrioxamine. Co-treatment with iron chelator prevented the suppression of phagocytic function in PMNs by iron sucrose. This observation excluded the possible contribution of the carbohydrate shell of iron sucrose to the PMN dysfunction. We next asked if iron sucrose affects the viability of PMNs. To this end, we compared the extent of apoptosis in blood samples incubated with or without iron sucrose. The experiments showed a significant dose-dependent increase in PMN apoptosis with iron sucrose. This observation points to the injurious effect of iron sucrose on PMNs which may, in part, account for the observed impairment of their phagocytic activity.
Phagocytosis is a major component of the host defense against microbial infection. Consequently, inhibition of phagocytic activity of PMNs by iron sucrose can contribute to an increased incidence and severity and poor outcome of bacterial infections in patients treated with excessive dose of this and other IV iron preparations. Besides suppression of phagocytic function of PMNs, iron overload can increase susceptibility to and severity of bacterial infections by promoting growth and enhancing virulence of bacteria [27, 28] . In order to acquire iron, bacteria compete with the host for the available iron by secreting low-molecular-weight iron chelators known as siderophores. These siderophores avidly bind free iron to form iron complexes which are taken up by microbe via receptor-mediated endocytosis [29, 30] . Under normal conditions nearly all of the plasma iron content is bound to transferrin which makes it inaccessible to the bacteria [27] . Administration of IV iron preparations results in rapid saturation of plasma transferrin and the rise in catalytically active non-transferrin-bound iron in the plasma, thereby providing readily accessible iron for bacteria. Thus, IV iron preparations may not only suppress the host's innate immune response but also increase the potential risk of infection. Interestingly, S. aureus possesses a transferrin receptor that allows it to acquire iron available in the bloodstream [29] .
The deleterious effect of iron sucrose on phagocytic activity in PMNs was compounded by the increased PMN apoptosis. This is most likely due to iron-induced oxidative stress in these cells. It should be noted that when compared to the intestinal absorption of 1-2 mg iron in the course of 3 meals per day, rapid IV infusion of large quantities of iron (100-1,000 mg) within a few minutes represents an enormous load with which the body is not accustomed. In fact, administration of these products has been shown to result in appearance of catalytically active non-transferrin-bound iron and a rise in markers of oxidative stress and inflammation in dialysis patients [31] [32] [33] [34] [35] . This is compounded by elevation of plasma hepcidin [36] which renders the ESRD patients particularly susceptible to the adverse effects of intravenously administered iron preparations especially when used indiscriminately. This is because by blocking ferroportin which is the main pathway of iron export in the macrophages and other reticuloendothelial cells, elevation of hepcidin leads to trapping and rapid expansion of iron pool in these cells. IV sucrose consists of a core of elemental iron covered by a carbohydrate envelope. Following their IV administration, these products are taken up by the reticuloendothelial cells which remove and release their carbohydrate moiety for clearance by the liver. The iron core is then used for storage in ferritin and release for binding to transferrin [37] . However, due to their massive load and rapid introduction, administration of these products leads to elevated levels of catalytically active iron within the cells and non-transferrin-bound iron in the plasma [38] . This leads to formation of iron-catalyzed hydroxyl radical and oxidative stress which can account for the PMN apoptosis observed in the present study [39] [40] [41] [42] [43] .
The results of the present in vitro study, which demonstrated a concentration-dependent suppression of PMN phagocytic capacity and viability by iron sucrose, parallel the findings of an earlier cross-sectional investigation of ESA-and IV iron-treated ESRD patients reported by Patruta et al. [22] . These investigators examined the phagocytic and bacteriocidal properties of PMN from subgroups of patients with a wide range of serum ferritin levels ( ! 60 to 1 650 g/l) against E. coli and found a significant association between ferritin level and impairment of PMN functions in hemodialysis patients. Based on these observations they cautioned against excessive use of IV iron in hemodialysis patients with elevated ferritin levels.
Conclusions
The results showed that iron sucrose at pharmacologically relevant concentrations significantly inhibits phagocytic function in PMNs against both Gram-positive and Gram-negative bacteria, and that the deleterious effect of iron sucrose was mediated by its elemental iron core but not its carbohydrate shell and as such may be shared by other IV iron preparations. Furthermore, iron sucrose significantly increased PMN apoptosis which may, in part, account for the observed impairment of their phagocytic activity. These findings build upon previous studies and provide compelling evidence for the potential adverse effects of the indiscriminate use of the IV iron preparations in the highly vulnerable patients with advanced CKD.
